SecBot SecBot
SECBOTREPLAY Home › Report › BIIB

BIIB · Biogen announced upcoming presentation of late-breaking Phase 2 (Part…

Biogen Inc. · PRESS-RELEASE filed Mar 19, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 19, 2026 at 07:30 ET

Biogen announced upcoming presentation of late-breaking Phase 2 (Part A) results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus (CLE) at the 2026 American Academy of Dermatology meeting. The data supported the FDA's recent Breakthrough Therapy Designation for litifilimab, a potential first-in-class monoclonal antibody targeting BDCA2, highlighting its safety and efficacy in a disease with no approved targeted therapies since the 1950s.

  • Litifilimab received FDA Breakthrough Therapy Designation for CLE based on Phase 2 LILAC and AMETHYST Part A results.
  • Late-breaking 24-week Phase 2 AMETHYST Part A data will be presented at AAD 2026, showing efficacy and safety in CLE.
  • Phase 3 part of AMETHYST is ongoing with data expected in 2027.
  • Litifilimab is a first-in-class anti-BDCA2 monoclonal antibody discovered in-house at Biogen.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access